Addiction, Author Interviews / 20.10.2024

MedicalResearch.com Interview with: Karen Arscott, DO Department of Medical Education Geisinger Commonwealth School of Medicine Scranton PA 18509 MedicalResearch.com: What is the background for this study? Response: “Substance Use Disorder Risk Assessment (SUDRA)” is a proposed screening tool and possible source of prevention for substance use disorder (SUD) and alcohol use disorder (AUD).  The US opioid overdose epidemic continues to escalate with over one-hundred thousand deaths in a single year. The current screening tools used for assessing SUD identifies persons already suffering with advanced disease. Our investigation brings to light a simple screening tool which can be used to identify a person with “Preaddiciton” potential. For many years I have asked persons (both patients and nonpatients) the question how they felt the first time they took an opioid. Their answers have been astonishing. Probably the one answer that struck me the strongest was a professional colleague who answered that when she was prescribed Vicodin following a surgical procedure it made her feel so amazing that it scared her, and she never took another opioid. She reported to me that it would have been too easy to take regularly for the wonderful feeling – she however, recognized the danger of that feeling and avoided a potential substance use disorder. What if this risk was provided to all – what if parents and patients understood the risk if faced with that “feeling”? How many lives could be saved? We are very confident that these timely findings will be discussed and presented widely. The paper will be highly downloaded and cited by many interested in the prevention of substance use disorder – a new concept and much improved over the current treatment of advanced disease. (more…)
Author Interviews, COVID -19 Coronavirus, JAMA, OBGYNE, Pediatrics / 16.10.2024

MedicalResearch.com Interview with: Eleni G. Jaswa, MD, MSc Assistant Professor, Ob/Gyn, Reproductive Science UCSF MedicalResearch.com: What is the background for this study? Response: Some infections during pregnancy have been associated with abnormal neurodevelopment in children. This is likely due to the infection itself, or the maternal immune system response to infection. We sought to determine whether maternal COVID-19 infection during pregnancy, a now common occurrence, was associated with changes in children's neurodevelopment out to 24-months-old, compared to control children not exposed to maternal COVID-19 in utero. (more…)
Alzheimer's - Dementia, Author Interviews, Cost of Health Care, Medicare, UCLA / 15.10.2024

MedicalResearch.com Interview with: Frank F. Zhou  |  he/him MD Candidate, Class of 2025 David Geffen School of Medicine at UCLA MedicalResearch.com: What is the background for this study? What is Lecanemab used for?  How is it given to patients? Response: Lecanemab is a new infusion therapy for Alzheimer's disease. Its dosing is based on each patient's body weight (10 mg/kg every two weeks), but the drug is only available in 500 mg and 200 mg single-use vials, meaning that any leftover drug in vials must be thrown away. Given that lecanemab is expected to cost Medicare billions of dollars each year, we hypothesized that discarded drug could result in significant wasteful spending. (more…)
Author Interviews, JAMA, Pharmaceutical Companies / 11.10.2024

MedicalResearch.com Interview with:

David-Dan Nguyen MDCM MPH Doctoral Student Institute of Health Policy Management and Evaluation and Resident Physician Division of Urology University of Toronto

MedicalResearch.com: What is the background for this study? Response: Peer reviewers are crucial to the academic publishing process. While there’s been significant scrutiny of potential conflicts of interest among authors and editors of major journals, the potential for conflicts of interest among peer reviewers has been relatively unexplored. As such, our study aimed to quantify and characterize industry payments made to peer reviewers of top medical journals—The BMJ, JAMA, The Lancet, and The New England Journal of Medicine—to better understand the extent of these financial relationships.  (more…)
Author Interviews, COVID -19 Coronavirus, Heart Disease / 10.10.2024

MedicalResearch.com Interview with: Stanley Hazen, MD, PhD Chair, Cardiovascular & Metabolic Sciences Lerner Research Institute CoSection head, Preventive Cardiology & Cardiovascular Rehabilitation Heart, Vascular and Thoracic Institute Cleveland Clinic MedicalResearch.com: What is the background for this study? Response:  One of the unique features of COVID is that in some subjects, there unfortunately appear to be long term adverse effects that can occur following resolution of the acute infection.  These studies add to the growing body of data showing that COVID-19 infection can enhance risk for experiencing adverse cardiac events (heart attack, stroke, and death) over time. (more…)
Author Interviews, Cancer Research, JAMA, Microbiome, NYU / 01.10.2024

MedicalResearch.com Interview with: Jiyoung Ahn, PhD Professor of Population Health, NYU Grossman School of Medicine Associate Director for Population Science, NYU Perlmutter Cancer Center NYU Langone Health Smilow Research Building New York, NY 10016 MedicalResearch.com: What is the background for this study? What are the main findings? Response: We found that oral bacterial species are linked to a collective 50% increased risk of developing head and neck squamous cell carcinoma (HNSCC). Some of these microbes have previously been shown to contribute to periodontal disease, a serious gum infection that can erode the jawbone and the soft tissues surrounding the teeth. (more…)
Author Interviews, Genetic Research, Nutrition, Pediatrics / 25.09.2024

MedicalResearch.com Interview with: Dr Zeynep Nas Ph.D. Postdoctoral Research Fellow Department of Behavioural Science and Health Institute of Epidemiology & Health Care University College London MedicalResearch.com: What is the background for this study? Response: We were interested in why some children are more selective in their food intake and more reluctant to try new foods compared to those who are not. We investigated this question in a twin study, which compares identical twins (who share all of their genes) to non-identical twins (who share half) to understand the relative influence of genetics versus the environment in shaping individual differences in fussy eating. (more…)
Author Interviews / 17.09.2024

Editor's note: If you purchase semaglutide or similar medications, be sure to be followed by your health care provider and verify that the supplier is reputable before your purchases. When it comes to weight loss, it often feels like everyone has an opinion. Some swear by keto, while others say it's all about intermittent fasting. And let’s not forget the ever-popular crash diets that promise instant results but leave you feeling sluggish and starving. With so much conflicting advice, how can you figure out what actually works? This post attempts to break down the science behind weight loss, cutting through the noise and getting to the core of what really makes a difference in shedding those extra pounds—without the fads. weight-obesity-scale

Calories In, Calories Out: The Basics

At its most fundamental level, weight loss comes down to one basic principle: calories in versus calories out. The idea is simple—if you consume fewer calories than your body needs, you'll lose weight. This is known as creating a calorie deficit. Your body has to find energy somewhere, and when you're not giving it enough through food, it starts to use stored fat. However, it's not always as straightforward as it seems. People have different metabolic rates, meaning some burn calories faster than others. Plus, hormones, genetics, and lifestyle factors can all affect how easy or difficult it is to drop pounds. This is why two people on the same diet might experience different results. Key takeaway: To lose weight, you need to consistently eat fewer calories than you burn. But keep in mind that individual factors can influence how quickly (or slowly) this happens for you. (more…)
Aging, Author Interviews, BMJ, Heart Disease, Statins / 11.09.2024

MedicalResearch.com Interview with: Borislava Mihaylova, DPhil Associate Professor & Senior Health Economist Nuffield Department of Population Health, University of Oxford, UK & Professor of Health Economics Wolfson Institute of Population Health Queen Mary University of London, UK MedicalResearch.com: What is the background for this study? Response: Despite high risks of heart disease and stroke in people over 70 years old and high need for preventive treatment such as statins, fewer older people use statins [compared to middle-aged people]. This, at least in part, is likely due to fewer older people, particularly those without previous heart attacks and strokes, included in the randomized studies of statin treatment. This has led to more limited evidence among them with larger uncertainty. Thus, we set to re-examine the value of statin treatment using the latest evidence and contemporary population data. (more…)
Author Interviews, Dental Research, Pediatrics / 10.09.2024

Are you considering Invisalign for your child in South Surrey but wondering how it differs from the treatment adults receive? This particular procedure has become a popular choice for orthodontic care, offering a discreet and convenient way to straighten teeth. However, the approach for children can differ significantly from that for adults. This article will explain what you need to know about Invisalign for kids and how it stands apart from adult dental treatments in South Surrey.

Understanding Invisalign for Kids

Invisalign South Surrey for Kids is specifically designed to cater to the unique dental needs of growing children. The treatment focuses on aligning teeth and guiding the proper jaw and teeth development. This early intervention is crucial in preventing more severe orthodontic issues later in life. While the clear aligners work similarly to those for adults, the process and considerations are different. (more…)
Author Interviews, Technology / 29.08.2024

The astonishing growth in technology is one of the most important events that has led to groundbreaking changes in the healthcare industry. The impact is increasingly due to the growing usage of mobile devices to track and monitor health. A mobile health monitoring app is a software application program that can be installed on a smartphone or a tablet computer to collect, store, and transmit information relating to personal health. Mobile health apps heavily depend on the data provided by various devices such as fitness trackers, and other wearables. The increasing number of mobile health apps reflects the great potential, with an expected global market value of $33.17 billion by 2023, with an anticipated rise to $88.70 billion in 2032.  

Benefits of Mobile Health Monitoring Apps

Real-Time Health Tracking: Using these applications individuals can easily track and monitor their health vitals to get instant insights and take timely actions if needed. Improved Patient Engagement: By having regular details about their health individuals can stay motivated to maintain their health at the top level. In this way, following treatment plans becomes easier. Remote Monitoring: mHealth apps open the door to remote treatment by allowing doctors to track the health vitals of patients from anywhere. Personalized Health Insights: Individuals get personalized advice from these health monitoring software solutions which simplifies health management. Cost Savings: Health monitoring applications can help identify serious medical conditions early. Early identification and treatment can save huge medical expenses. (more…)
Alzheimer's - Dementia, Author Interviews / 29.08.2024

stethoscope-alzheimers-article

Alzheimer’s disease is the most common condition that leads to a gradual loss of memory and thinking skills. It’s marked by the buildup of plaques and tangles in the brain. It’s one of many different areas where Anavex Life Sciences is focusing its research as part of its mission to develop effective therapeutics for neurodegenerative disorders. In 1984, researchers discovered that a protein called amyloid beta is a key part of the plaques that aggregate in the brain. This led to the theory that Aβ is central to Alzheimer’s, known as the "amyloid cascade hypothesis." Since then, most Alzheimer’s treatments have targeted Aβ. However, many of these treatments have failed in clinical trials, leading to questions about this approach. Aβ is created from a larger protein called amyloid precursor protein through a series of steps involving different enzymes. Normally, APP is processed in a way that prevents the formation of Aβ. However, under certain conditions, the enzymes BACE1 and γ-secretase cut APP in a way that produces Aβ. Once formed, Aβ needs to be cleared from the brain to prevent harmful buildup. Aβ clearance involves several pathways, including enzyme degradation, transport across the blood-brain barrier, and removal through the brain’s fluid drainage systems. The blood-brain barrier is a network of cells that controls what enters and leaves the brain. Specific proteins help move Aβ out of the brain, but for those with Alzheimer’s, these proteins don’t work as well, leading to Aβ accumulation. Genetic studies show that Aβ buildup plays a significant role in the disease. For example, people with Down syndrome, who have an extra copy of the APP gene, often develop Alzheimer’s. Mutations in genes related to APP processing can also cause early-onset Alzheimer’s, while certain mutations can protect against it. Both genetic and lifestyle factors, like diabetes and lack of exercise, can increase Aβ production or hinder its clearance. Despite setbacks, there are promising developments in Aβ-based therapies. Aducanumab, an antibody that targets Aβ, was approved by the FDA for its ability to reduce Aβ plaques in early Alzheimer’s patients. Another antibody, donanemab, has shown even better results in clearing Aβ from the brain. Similarly, lecanemab, which targets soluble forms of Aβ, has been shown to reduce amyloid levels and improve cognitive function. Another drug, Anavex 2-73 (blarcamesine), has shown potential in reducing Alzheimer’s symptoms and brain changes in animal studies and a late stage human trial. Blarcamesine is a formulation of Anavex, a clinical-stage biopharmaceutical company that develops therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease and other central nervous system disorders. These advances offer new hope that targeting Aβ could still be a valid approach to treating Alzheimer’s. (more…)
Author Interviews, Cognitive Issues, Environmental Risks, NIH, Pediatrics / 27.08.2024

MedicalResearch.com Interview with: Rick Woychik, Ph.D. Director of the National Toxicology Program Director of the National Institute of Environmental Health Sciences Principal Investigator Mammalian Genome Research Group Division for Intramural Research at NIEHS MedicalResearch.com: What is the background for this study? Response: Since 1945, the use of fluoride has been a successful public health initiative for reducing dental cavities and improving general oral health of adults and children. There is a concern, however, that some pregnant women and children may be getting more fluoride than they need because they now get fluoride from many sources including treated public water, water-added foods and beverages, teas, toothpaste, floss, and mouthwash, and the combined total intake of fluoride may exceed safe amounts.   Therefore, the National Toxicology Program (NTP) conducted a systematic review of the published scientific literature on the association between fluoride exposure and neurodevelopment and cognition. The NTP released their findings in a State of the Science Monograph on August 21, 2024, and posted to the NTP website. A corresponding meta-analysis on children’s IQ has been accepted by a scientific journal for publication later in 2024. The NTP started this work in 2016. As with all research documents intended for publication, the NTP fluoride monograph and meta-analysis underwent rigorous scientific evaluation.  The evaluation process has involved many steps. The draft fluoride monograph received significant critical feedback during peer-review by the National Academies of Science, Engineering and Medicine (NASEM), from other external experts, and from experts in several federal health agencies.  After modifications were made, additional evaluation following a rigorous scientific framework was conducted by subject matter experts organized by the NTP Board of Scientific Counselors. I am very pleased that this document is now complete and available for reference. Since fluoride is such an important topic to the public and to public health officials, it was imperative that we made every effort to get the science right. I commend the report authors, the NTP Board of Scientific Counselors, and countless subject matter experts who participated in this evaluation. The monograph represents a thorough review of the data, and the various interpretations of the data, to accurately reflect what we know and where additional research is needed. (more…)
Author Interviews, Autism, Brigham & Women's - Harvard, Genetic Research / 26.08.2024

MedicalResearch.com Interview with: Caroline Dias, M.D., Ph.D. Assistant Professor, Pediatrics-Developmental Pediatrics University of Colorado Anschutz Medical Campus       Christopher Walsh, M.D., Ph.D. Chief, Division of Genetics and Genomics Bullard Professor of Pediatrics and Neurology at Harvard Medical School and researcher who has used material donated to the brain bank     MedicalResearch.com: What is the background for this study? Response: Many different types of genetic variants contribute to neurodevelopmental disorders such as autism. Copy number variants are large pieces of genetic material that are duplicated or deleted. We have known for many years that many copy number variants at certain genetic locations are linked to autism. Because these copy number variants may include lots of different genes, it has been difficult to understand how these copy number variants alter human brain function. Furthermore, although animal models are important, autism is in many ways defined by differences in uniquely human cognitive and social functioning. Better understanding of how these copy number variants change human brain function will shed light on universal mechanisms that regulate neurodevelopment. We studied a copy number variant called dup15q, that is associated with almost 40-fold higher rates of autism vs. the general population. We studied post-mortem human brain tissue from individuals with dup15q, individuals with autism not related to dup15q, and neurotypical controls, to better understand how the human brain is impacted by dup15q. We focused on frontal cortex, an important brain region in executive function and social perspective taking. We applied cutting edge techniques that allow us to assess individual cells in the brain.  (more…)
Author Interviews / 23.08.2024

Editor’s note:  “FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders”. Do not take ketamine without the supervision of a health care professional trained in the specific use of ketamine. How Ketamine Therapy is Transforming Depression Treatment in NYC Depression is a pervasive mental health condition affecting millions of people worldwide. Traditional treatments like antidepressants and psychotherapy can be effective, but they often take weeks to show results and may not work for everyone. Ketamine therapy has emerged as a groundbreaking approach, offering new hope for those struggling with severe depression. In this article, we’ll explore ketamine therapy for depression in New York City and what you need to know about this innovative therapy. What is Ketamine Therapy? Ketamine therapy involves using ketamine, a medication originally developed as an anesthetic, to treat depression. In recent years, research has shown that ketamine can have rapid and profound effects on mood, particularly in individuals with treatment-resistant depression. (more…)
Anemia, Author Interviews, JAMA, OBGYNE / 23.08.2024

Esa M. Davis, M.D., M.P.H , F.A.A.F.P Professor of Medicine and Family and Community Medicine Associate Vice President of Community Health and Senior Associate Dean of pPopulation Health and Community Medicine University of Maryland School of Medicine Dr. Davis joined the U.S. Preventive Services Task Force in January 2021     MedicalResearch.com: What is the background for this study? What are the main findings? Response: Iron is important to overall health, and people need more iron when they are pregnant. This can make pregnant people at increased risk for iron deficiency, which can progress to anemia and cause complications for both moms and their babies. After reviewing the latest available research, the Task Force found that there is not enough evidence on whether pregnant people who do not have signs or symptoms of iron deficiency or anemia should be screened—or take iron supplements—to improve their health or the health of their baby.   (more…)
Author Interviews, Science, Sleep Disorders / 18.08.2024

MedicalResearch.com Interview with: Azahara Oliva PhD Assistant Professor Department of Neurobiology and Behavior Cornell University   MedicalResearch.com: What is the background for this study? What are the main findings? Response: The background is that we knew for a while now that neurons work hard to consolidate into memories each experience that we have during the day. But at the same time, it is known that sleep restore activity of our body and physiology. How was that possible? How can the neurons in our brain "work hard" during the time that we are supposed to be restoring our vitals? We found that in between their hard work, during sleep, our neurons take "breaks of activity" so our brain can build memories with precision. (more…)
Addiction, Author Interviews, Cannabis / 05.08.2024

MedicalResearch.com Interview with: Luke Cavanah, BS Department of Medical Education Geisinger Commonwealth School of Medicine Scranton, PA 18509 MedicalResearch.com: What is the background for this study? Response: Amphetamine, lisdexamfetamine, and methylphenidate, are first-line treatments for attention-deficit hyperactivity disorder (ADHD) and are classified as Schedule II stimulants due to their risk of addiction. (1–3) There has been high and increasing use and misuse of these medications with inadequate explanation. (4)  Since chronic cannabis use can result in similar cognitive effects as ADHD 5–7, we wondered if more stimulants were prescribed for what appeared to be ADHD but was a consequence of chronic cannabis use. In other words, has the legalization of cannabis contributed to this inadequately explained increase in stimulant use? A recent study by our lab group that looked at the slopes of stimulant distribution rates over time -- before and after medical cannabis legalization -- did not support this.(8) Given the prevalence and increasing legalization of recreational cannabis, we wanted to determine how slopes of stimulant distribution rates compared before and after recreational cannabis legalization. (more…)
Author Interviews, Cancer Research / 01.08.2024

MedicalResearch.com Interview with: Dr Meena Rafiq | Academic GP & Clinical Research Fellow FRACGP MRCGP MBBS BSc MSc Epidemiology of Cancer and Healthcare Outcomes (ECHO) Group, UCL Department of General Practice, The University of Melbourne UCL Department of Behavioural Science and Health     MedicalResearch.com: What is the background for this study? What are the main findings? Response: Almost all patients with cancer will first see their GP with symptoms and half of these patients will have vague, non-specific symptoms. As a GP I know it can be challenging to pick up patients with possible cancer in a 10 minute GP appointment, especially if they have vague non-specific symptoms. We know that many of these patients are already having blood tests done by their GP. So, we wanted to see if any of these blood tests could be used to help pick up with patients who see their GP with vague abdominal symptoms like abdominal pain and bloating are most likely to have cancer and need to be urgently referred. (more…)
AI and HealthCare, Author Interviews, Technology / 29.07.2024

Imagine a world where your health plan is as unique as your fingerprint. That's not a far-off dream - it's happening right now. In 2022, the global wellness industry hit a staggering $5.6 trillion, showing just how much people care about their health. But here's the thing: we're all different. What works for your neighbor might not work for you. That's where personalized wellness plans come in, and they're getting a big boost from technology. Think of it as having a super-smart health coach in your pocket. Thanks to AI in healthcare, we can now crunch huge amounts of data to create health plans that fit you perfectly. From your DNA to your daily habits, these tech tools consider it all. This article will explore how these amazing technological advancements are changing the game in wellness. We'll see how they're making it possible to create health strategies that are truly tailored to you, helping everyone live their best, healthiest life. (more…)
Author Interviews, Parkinson's / 25.07.2024

MedicalResearch.com Interview with: Gus Alva, MD, DFAPA Medical Director, ATP Clinical Research Medical Director, Senior Brain Health, Hoag Hospital, Newport Beach, Assistant Professor, Department of Psychiatry and Neuroscience University of California, Riverside, CA MedicalResearch.com: What is the background for this study? Response: This trial evaluated the effects of pimavanserin compared to placebo in frail older adults and elderly patients with neuropsychiatric symptoms related to Neurodegenerative disorder (NDD), such as hallucinations and delusions, to better understand the safety of pimavanserin in this population. The study was a phase 3b, 8-week treatment (study duration of up to 16 weeks) with the primary endpoint being safety and tolerability, measured by treatment-emergent adverse events (TEAEs). Secondary safety endpoints were change from baseline in motor and cognitive function; exploratory endpoints included suicidality, sleep quality, and neuropsychiatric symptoms. The reason for doing this study is that there is a high degree of interest in further understanding the safety of pimavanserin, as many antipsychotics used off label often have significant and serious adverse effects, including risk of falls, parkinsonism, and death. (more…)
Author Interviews, Diabetes, Pediatrics / 23.07.2024

MedicalResearch.com Interview with: Prof. Richard Oram PhD Associate Professor, Diabetes UK Harry Keen Fellow Institute of Biomedical and Clinical Science and NIHR Exeter Clinical Research Facility University of Exeter MedicalResearch.com: What is the background for this study? Response: In contrast to most autoimmune diseases, male sex is a risk factor for type 1 diabetes (T1D). This raises the hypothesis that either immune, metabolic, or other differences between sexes may impact risk or progression through stages of T1D. However, understanding the mechanisms for this could inform future interventions or risk stratification of individuals at-risk of T1D. (more…)
Author Interviews, Diabetes, Johns Hopkins, Nutrition / 22.07.2024

MedicalResearch.com Interview with: Shutong Du Welch Center for Prevention, Epidemiology, and Clinical Research Department of Epidemiology, Bloomberg School of Public Health Johns Hopkins University, Baltimore, MD MedicalResearch.com: What is the background for this study? Response: We know that ultra-processed foods (UPFs) are high in salt, added sugars, unhealthy fats, and artificial additives and have undergone multiple industrial processes. These foods have been linked to adverse health outcomes like weight gain and cardiovascular diseases. Despite these risks, current diabetes guidelines do not address UPFs. (more…)
Author Interviews, OBGYNE, Radiology / 22.07.2024

MedicalResearch.com Interview with: Nicole Lamparello, M.D Interventional Radiologist Assistant Professor of Radiology Weill Cornell Medicine Assistant Attending Radiologist NewYork-Presbyterian Hospital/Weill Cornell Medicine MedicalResearch.com: What is the background for this study? Would you briefly describe the condition of Uterine Fibroids? Response: A uterine fibroid (leiomyoma) is a type of tumor that grows in the uterus..  Most fibroids are benign growths that do not spread to other regions of the body.  However, fibroids can cause a variety of symptoms that severely impact a woman’s quality of life, including pelvic pressure or pain, heavy menstrual bleeding, abdominal bloating, urinary urgency/retention and infertility. Often, women with uterine fibroids are presented with hysterectomy as a treatment option, and are not informed about less-invasive options, such as Uterine Fibroid Embolization (UFE), a non-surgical procedure performed by an interventional radiologist. (more…)
Author Interviews / 12.07.2024

The integration of Proposal Automation with customer relationship management (CRM) systems is revolutionizing the way businesses create, manage, and track their sales proposals. This synergy unlocks efficiencies, enhances customer interactions, and provides valuable insights that drive business growth. Understanding this integration is vital if you aim to streamline your sales processes and establish deeper customer connections. Below, we discuss the transformative impact of combining these technologies on your sales strategy.

Understanding the Synergy Between Proposal Automation and CRM Systems

A team in an office discussing proposal automation during a meetingAt its core, Proposal Automation streamlines the creation of complex sales proposals, allowing businesses to generate accurate, personalized proposals swiftly. This is particularly beneficial in today's fast-paced market where quick turnaround times can be a competitive edge. Meanwhile, CRM systems are designed to manage customer interactions and data throughout the customer lifecycle. They help companies understand their customers, manage relationships, and analyze data for better decision-making. When Proposal Automation is integrated with CRM systems, it allows for seamless access to customer data and insights. This integration helps in customizing proposals based on past interactions, purchasing history, preferences, and more. Proposal creation becomes significantly faster and more personalized, which resonates well with potential clients. By leveraging these combined capabilities, businesses can create highly targeted sales pitches that align with customer expectations. The marriage of these systems is not just about convenience—it's also about leveraging data to make informed decisions. A CRM laden with valuable customer data, when connected with proposal automation, enables sales teams to craft data-driven proposals. This strategic approach can significantly increase the chances of closing deals, as proposals are backed by insights rather than assumptions. (more…)